{
  "title": "Prognostic Scores: International Prognostic Index (IPI) – Non-Hodgkin Lymphoma (NHL)",
  "category": "Hematologic Malignancies",
  "section": "Lymphoma",
  "summary": "Comprehensive guide to the International Prognostic Index (IPI) and its modern variants for risk stratification in aggressive non-Hodgkin lymphomas.",
  "author": "OncoVISTA Team",
  "lastUpdated": "2023-11-20T00:00:00Z",
  "version": "2.1.0",
  "metadata": {
    "reviewStatus": "peer-reviewed",
    "readingTimeMinutes": 12,
    "relatedTopics": [
      "Diffuse Large B-Cell Lymphoma Management",
      "Lymphoma Staging Systems",
      "Molecular Prognostics in Hematologic Malignancies"
    ]
  },
  "content": [
    {
      "type": "heading",
      "level": 2,
      "text": "Prognostic Scores"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Topic 3: International Prognostic Index (IPI) – Non-Hodgkin Lymphoma (NHL)"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "1. Introduction"
    },
    {
      "type": "paragraph",
      "text": "The International Prognostic Index (IPI) is the most established clinical risk stratification tool for aggressive non-Hodgkin lymphomas (NHLs), especially diffuse large B-cell lymphoma (DLBCL). It predicts overall survival and treatment response, allowing oncologists to personalize therapy and guide patient counseling."
    },
    {
      "type": "paragraph",
      "text": "Despite being developed over 30 years ago, IPI remains clinically relevant, especially in settings lacking genomic testing or advanced imaging. Modern adaptations—R-IPI, NCCN-IPI, and biological IPI—have extended its value in the era of rituximab and beyond."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "2. Historical Context"
    },
    {
      "type": "list",
      "items": [
        "Introduced in 1993 by an international collaboration using outcomes data from >2000 patients treated with CHOP-like chemotherapy.",
        "The IPI aimed to simplify risk prediction for DLBCL and other aggressive NHLs using five easily obtainable clinical variables.",
        "Since then, it has been refined to match therapeutic advances (e.g., R-CHOP, PET-CT staging)."
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "3. Classic IPI: Five Risk Factors"
    },
    {
      "type": "paragraph",
      "text": "Each variable scores 1 point, with a total possible score from 0–5."
    },
    {
      "type": "table",
      "headers": ["Risk Factor", "Threshold"],
      "rows": [
        ["Age", "> 60 years"],
        ["ECOG Performance Status", "≥ 2"],
        ["Serum LDH", "Above upper limit"],
        ["Ann Arbor Stage", "III or IV"],
        ["Extranodal Sites Involved", "More than 1"]
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "4. Risk Group Classification"
    },
    {
      "type": "table",
      "headers": ["IPI Score", "Risk Group", "5-Year OS (Pre-Rituximab)"],
      "rows": [
        ["0–1", "Low", "~73%"],
        ["2", "Low-Intermediate", "~51%"],
        ["3", "High-Intermediate", "~43%"],
        ["4–5", "High", "~26%"]
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Limitation: Original IPI does not account for biologic heterogeneity, rituximab-era outcomes, or PET-based response metrics."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "5. Revised IPI (R-IPI)"
    },
    {
      "type": "paragraph",
      "text": "Developed to reflect improved survival in the R-CHOP era (post-rituximab), it simplifies stratification into three groups:"
    },
    {
      "type": "table",
      "headers": ["Group", "IPI Score", "4-Year OS"],
      "rows": [
        ["Very Good", "0", "~94%"],
        ["Good", "1–2", "~79%"],
        ["Poor", "3–5", "~55%"]
      ]
    },
    {
      "type": "paragraph",
      "text": "R-IPI is commonly used in clinical practice for DLBCL treated with immunochemotherapy."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "6. NCCN-IPI (2014)"
    },
    {
      "type": "paragraph",
      "text": "A further refinement developed by the National Comprehensive Cancer Network (NCCN):"
    },
    {
      "type": "list",
      "items": [
        "Stratifies age more precisely (e.g., <40, 41–60, 61–75, >75).",
        "Highlights high-risk extranodal involvement (e.g., CNS, bone marrow, GI tract, liver).",
        "Improves prognostic accuracy in rituximab-treated cohorts."
      ]
    },
    {
      "type": "table",
      "headers": ["NCCN-IPI Score", "Risk Group", "5-Year OS"],
      "rows": [
        ["0–1", "Low", "~96%"],
        ["2–3", "Low-Intermediate", "~82%"],
        ["4–5", "High-Intermediate", "~64%"],
        ["6–8", "High", "~33%"]
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "7. Clinical Applications of IPI and Its Derivatives"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "✅ Widely used for:"
    },
    {
      "type": "list",
      "items": [
        "Initial risk stratification",
        "Identifying candidates for consolidative radiation or stem cell transplant",
        "Decisions on CNS prophylaxis (e.g., in cases of elevated LDH and extranodal involvement)",
        "Stratification in clinical trials"
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "❌ Not used for:"
    },
    {
      "type": "list",
      "items": [
        "Indolent lymphomas (e.g., follicular lymphoma)",
        "Primary CNS lymphoma",
        "Peripheral T-cell lymphoma (distinct biology and natural history)"
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "8. Biological IPI and Molecular Refinement"
    },
    {
      "type": "paragraph",
      "text": "While still under investigation, the biological IPI (B-IPI) aims to enhance prognostication through:"
    },
    {
      "type": "table",
      "headers": ["Biomarker", "Prognostic Insight"],
      "rows": [
        ["MYC, BCL2, BCL6", "Double-hit lymphomas → high risk"],
        ["Cell of Origin (GCB vs ABC)", "Distinct outcomes, influences therapy"],
        ["PET-CT Deauville Score", "Dynamic response prediction"],
        ["Gene expression profiling", "Improved subtype precision"]
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Integrated models combining clinical + imaging + molecular data are the future of lymphoma prognostics."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "9. IPI vs Interim PET/CT"
    },
    {
      "type": "table",
      "headers": ["Modality", "Purpose", "Use Case"],
      "rows": [
        ["IPI", "Baseline static risk", "Initial treatment decisions"],
        ["Interim PET/CT", "Dynamic response prediction", "Adapt treatment based on early response"]
      ]
    },
    {
      "type": "paragraph",
      "text": "Combining IPI and PET improves risk-adaptive treatment strategies, especially in trials."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "10. Role in the CAR-T and Novel Therapy Era"
    },
    {
      "type": "paragraph",
      "text": "Even in the age of CAR-T:"
    },
    {
      "type": "list",
      "items": [
        "IPI remains relevant pre-CAR-T, guiding patient selection, bridging therapy, and post-infusion expectations.",
        "Novel scores (e.g., CARTITUDE, ZUMA-derived models) incorporate IPI alongside inflammatory and immune markers."
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "11. Limitations and Updates"
    },
    {
      "type": "table",
      "headers": ["Challenge", "Strategy"],
      "rows": [
        ["Pre-rituximab outcome bias", "Use R-IPI or NCCN-IPI"],
        ["Non-uniform extranodal risk weighting", "NCCN-IPI addresses this"],
        ["Exclusion of genomic profiling", "Consider adding NGS/IHC data"],
        ["Inapplicability to some NHL subtypes", "Use disease-specific tools"]
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "12. Comparison Summary: IPI Variants"
    },
    {
      "type": "table",
      "headers": ["Score", "Key Features", "Best Use Case"],
      "rows": [
        ["IPI", "5 clinical variables", "Legacy tool, resource-limited settings"],
        ["R-IPI", "Simplified 3-tier risk model", "Post-rituximab, routine clinical use"],
        ["NCCN-IPI", "Granular age and site data", "High-precision DLBCL prognostication"],
        ["B-IPI", "Includes biologic markers, GEP, PET data", "Precision oncology and research use"]
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "13. Summary"
    },
    {
      "type": "paragraph",
      "text": "The IPI remains the cornerstone of risk stratification in aggressive NHL. While newer models improve accuracy, its simplicity and historical utility make it indispensable. Clinicians must now adapt IPI-based frameworks with:"
    },
    {
      "type": "list",
      "items": [
        "Biologic markers",
        "Imaging data",
        "Patient-specific comorbidities and goals"
      ]
    },
    {
      "type": "paragraph",
      "text": "This integrated approach ensures personalized therapy and better-informed patient discussions."
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Key Clinical Takeaways"
    },
    {
      "type": "numbers",
      "items": [
        "Use classic IPI for initial risk stratification in DLBCL",
        "Prefer R-IPI or NCCN-IPI for patients receiving rituximab-containing regimens",
        "Consider molecular testing (MYC/BCL2/BCL6) for high-risk cases",
        "Combine with interim PET/CT for dynamic risk assessment",
        "IPI remains relevant even in novel therapy paradigms like CAR-T"
      ]
    }
  ]
}